Each experiment was conducted in duplicate (n = 2) for the pure compounds and physical mixtures, and as a single run for the powderized tablets. The weight loss (corresponding to the water content) was determined using the TA Instruments TRIOS software (version 5.1.1). Drug crystallinity of the pure substances, physical mixtures and powderized AMF-exposed tablets was analyzed with an X-Ray powder X'Pert Pro diffractometer (PANalytical, The Netherlands) using Cu Kα radiation (λ = 1.54187 Å). The diffractograms were recorded from 2θ 5° to 30° at 45 kV and 40 mA. As the superparamagnetic nanoparticles fluoresce, the pulse height distribution level was adjusted to 40-80% of the energy to compensate for the baseline drift and to obtain a higher signal-to-noise ratio. The diffractograms were analyzed using the X'Pert HighScore Plus software (version 2.2.4). Differential scanning calorimetry (DSC; Discovery, TA Instruments, USA) scans were collected for the physical mixtures and the AMF-exposed tablets. All experiments were conducted under a nitrogen gas purge of 50 mL min -1 . Using physical mixtures of 10-50 wt% celecoxib in PVP (in 10% increments), the melting enthalpy of the depressed melting was determined and fitted with a second degree polynomial function. The calibration experiments were conducted in duplicate (n = 2). 3-5 mg of each sample was weighted in Tzero aluminum pans with hermetic lids. The lid was perforated to allow water evaporation. A modulated DSC (mDSC) run was performed at a heating rate of 3 °C min -1 from -20 °C to 170 °C after an isothermal period of 2 min. The modulation had an amplitude of 1 °C min -1 at a period of 50 sec. The melting enthalpy was determined in the total heat flow signal. Each experiment was conducted once (n = 1). The sample mass and melting enthalpy were corrected for the water content determined by TGA. Using the calibration fitting, the crystallinity was calculated from the determined melting enthalpy. The relative residual crystallinity was calculated by dividing it with the crystallinity of celecoxib in the physical mixtures, i.e., before exposure to the magnetic field. Degree of drug amorphization (%) is the noncrystalline fraction calculated from the relative residual crystallinity. The melting enthalpy was determined using the TRIOS software from TA Instruments (version 5.1.1).